At present, there is only one prior report of recurrent POLE-mutated glioblastoma displaying a protracted response to pembrolizumab and bevacizumab.8 Taken together, the prolonged response seen in our patients was more likely due to either pembrolizumab or pembrolizumab plus bevacizumab. Here, POLE is linked to glioblastoma.